PE20100147A1 - PRODUCCION DE a-BETA - Google Patents

PRODUCCION DE a-BETA

Info

Publication number
PE20100147A1
PE20100147A1 PE2009001268A PE2009001268A PE20100147A1 PE 20100147 A1 PE20100147 A1 PE 20100147A1 PE 2009001268 A PE2009001268 A PE 2009001268A PE 2009001268 A PE2009001268 A PE 2009001268A PE 20100147 A1 PE20100147 A1 PE 20100147A1
Authority
PE
Peru
Prior art keywords
cumulative
crop
amino acid
period
glutamine
Prior art date
Application number
PE2009001268A
Other languages
English (en)
Inventor
Denis Drapeau
James R Mercer
Yen-Tung Luan
Daniel R Lasko
Wenge Wang
Original Assignee
Wyeth Res Ireland Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wyeth Res Ireland Ltd filed Critical Wyeth Res Ireland Ltd
Publication of PE20100147A1 publication Critical patent/PE20100147A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/0018—Culture media for cell or tissue culture
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/04—Plant cells or tissues
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/05—Inorganic components
    • C12N2500/10—Metals; Metal chelators
    • C12N2500/20—Transition metals
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/30—Organic components
    • C12N2500/32—Amino acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells
    • C12N2510/04—Immortalised cells

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Cell Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Botany (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)

Abstract

REFERIDA A UN METODO PARA PRODUCIR UN ANTI-ABETA EN UN CULTIVO CELULAR DE PRODUCCION A GRAN ESCALA, EL CUAL COMPRENDE: PROPORCIONAR UN CULTIVO CELULAR QUE COMPRENDE CELULAS DE MAMIFERO QUE CONTIENEN UN GEN QUE CODIFICA UN ANTI-ABETA, CUYO GEN SE EXPRESA BAJO UNA CONDICION DE CULTIVO CELULAR; Y UN MEDIO QUE CONTIENE GLUTAMINA Y QUE TIENE UNA CARACTERISTICA DE MEDIO SELECCIONADA DE: (I) UNA CANTIDAD DE AMINOACIDO ACUMULATIVO POR VOLUMEN UNITARIO MAYOR DE 70 mM, (ii) UNA RELACION MOLAR DE GLUTAMINA ACUMULATIVA A ASPARAGINA ACUMULATIVA DE MENOS DE 2, (iii) UNA RELACION DE GLUTAMINA ACUMULATIVA MOLAR A AMINOACIDO ACUMULATIVO TOTAL DE MENOS DE 0,2, (iv) UNA RELACION DE ION INORGANICO ACUMULATIVO MOLAR A AMINOACIDO TOTAL ACUMULATIVO DE ENTRE 0,4 A 1, (v) UNA CANTIDAD ACUMULATIVA COMBINADA DE GLUTAMINA Y ASPARAGINA POR VOLUMEN UNITARIO DE MAS DE 16 mM, Y COMBINACIONES DE LOS MISMOS; MANTENER DICHO CULTIVO EN UNA FASE DE CRECIMIENTO INICIAL BAJO UN PRIMER GRUPO DE CONDICIONES DE CULTIVO DURANTE UN PRIMER PERIODO DE TIEMPO TALES COMO TEMPERATURA DE ENTRE 30ºC Y 42ºC POR UN PERIODO DE 0-8 DIAS; CAMBIAR POR LO MENOS UNA DE LAS CONDICIONES DE CULTIVO, DE MODO QUE SE APLIQUE UN SEGUNDO GRUPO DE CONDICIONES CON UN LIMITE DE TEMPERATURA ENTRE 25ºC Y 41ºC; MANTENER DICHO CULTIVO DURANTE UN SEGUNDO PERIODO DE MODO QUE SE ACUMULE EL ANTI-ABETA EN EL CULTIVO
PE2009001268A 2004-08-27 2005-08-26 PRODUCCION DE a-BETA PE20100147A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US60493604P 2004-08-27 2004-08-27

Publications (1)

Publication Number Publication Date
PE20100147A1 true PE20100147A1 (es) 2010-03-02

Family

ID=35500647

Family Applications (2)

Application Number Title Priority Date Filing Date
PE2009001268A PE20100147A1 (es) 2004-08-27 2005-08-26 PRODUCCION DE a-BETA
PE2005000986A PE20060715A1 (es) 2004-08-27 2005-08-26 Proceso de produccion de anti - abeta

Family Applications After (1)

Application Number Title Priority Date Filing Date
PE2005000986A PE20060715A1 (es) 2004-08-27 2005-08-26 Proceso de produccion de anti - abeta

Country Status (27)

Country Link
US (1) US7335491B2 (es)
EP (2) EP2348126A3 (es)
JP (3) JP2008511328A (es)
KR (1) KR100998857B1 (es)
CN (1) CN101048512B (es)
AR (1) AR050471A1 (es)
AU (1) AU2005280090A1 (es)
BR (1) BRPI0514680A (es)
CA (1) CA2578137C (es)
CR (1) CR8996A (es)
EC (1) ECSP077351A (es)
EG (1) EG25848A (es)
ES (1) ES2599103T3 (es)
HN (1) HN2005000486A (es)
IL (1) IL181587A (es)
MX (1) MX2007002382A (es)
MY (1) MY146097A (es)
NO (1) NO20071571L (es)
NZ (1) NZ591233A (es)
PE (2) PE20100147A1 (es)
RU (1) RU2418858C2 (es)
SG (1) SG155250A1 (es)
SV (1) SV2006002212A (es)
TW (1) TWI374935B (es)
UA (1) UA89644C2 (es)
WO (1) WO2006026408A2 (es)
ZA (1) ZA200702487B (es)

Families Citing this family (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10303974A1 (de) 2003-01-31 2004-08-05 Abbott Gmbh & Co. Kg Amyloid-β(1-42)-Oligomere, Verfahren zu deren Herstellung und deren Verwendung
TWI384069B (zh) 2004-08-27 2013-02-01 Pfizer Ireland Pharmaceuticals 多胜肽之製法
US7300773B2 (en) 2004-08-27 2007-11-27 Wyeth Research Ireland Limited Production of TNFR-Ig
TWI374935B (en) 2004-08-27 2012-10-21 Pfizer Ireland Pharmaceuticals Production of α-abeta
AR058140A1 (es) * 2005-10-24 2008-01-23 Wyeth Corp Metodo de produccion proteica utilizando compuestos anti-senescencia
US20070231895A1 (en) * 2005-11-02 2007-10-04 Lee Gene W Methods for adapting mammalian cells
KR20140087058A (ko) 2005-11-30 2014-07-08 애브비 인코포레이티드 아밀로이드 베타 단백질에 대한 모노클로날 항체 및 이의 용도
PT2289909E (pt) 2005-11-30 2015-02-10 Abbvie Inc Método de rastreio, processo de purificação de globulómeros a-beta não difundíveis, anticorpos selectivos contra os referidos globulómeros a-beta não difundíveis e processo para o fabrico dos referidos anticorpos
BRPI0619748B8 (pt) * 2005-12-12 2021-05-25 Ac Immune Sa anticorpo monoclonal, polinucleotídeo, composição, mistura, uso de um anticorpo monoclonal ou uma parte funcional do mesmo, método para preparar uma composição farmacêutica, linhagem celular de hibridoma isolado, método de diagnóstico de uma doença ou condição associada a amilóide em um paciente, método para diagnosticar uma predisposição para uma doença ou condição, método para monitorar doença residual mínima, método para prever a responsividade de um paciente e kits de teste
AU2007272957B2 (en) * 2006-07-13 2014-05-01 Wyeth Llc Production of glycoproteins
CA2657681C (en) * 2006-07-14 2019-03-19 Ac Immune S.A. Humanized antibodies against beta amyloid protein
EP2064315B1 (en) * 2006-11-03 2015-05-13 Wyeth LLC Glycolysis-inhibiting substances in cell culture
ES2538986T3 (es) * 2006-11-08 2015-06-25 Wyeth Llc Medios diseñados racionalmente para un cultivo celular
US8455626B2 (en) 2006-11-30 2013-06-04 Abbott Laboratories Aβ conformer selective anti-aβ globulomer monoclonal antibodies
US20100311767A1 (en) * 2007-02-27 2010-12-09 Abbott Gmbh & Co. Kg Method for the treatment of amyloidoses
AU2008220785B2 (en) 2007-03-01 2013-02-21 Vivoryon Therapeutics N.V. New use of glutaminyl cyclase inhibitors
EP2924113B1 (en) * 2007-03-02 2019-04-10 Wyeth LLC Use of copper and glutamate in cell culture for production of polypeptides
US9656991B2 (en) 2007-04-18 2017-05-23 Probiodrug Ag Inhibitors of glutaminyl cyclase
TW200902708A (en) * 2007-04-23 2009-01-16 Wyeth Corp Methods of protein production using anti-senescence compounds
KR101574355B1 (ko) 2007-04-26 2015-12-11 추가이 세이야쿠 가부시키가이샤 고농도 아미노산 함유 배지를 사용한 세포의 배양 방법
JP2010530744A (ja) * 2007-06-12 2010-09-16 エーシー イミューン ソシエテ アノニム アミロイドβに対するヒト化抗体
US8048420B2 (en) * 2007-06-12 2011-11-01 Ac Immune S.A. Monoclonal antibody
US8613923B2 (en) * 2007-06-12 2013-12-24 Ac Immune S.A. Monoclonal antibody
PT2238166E (pt) * 2007-10-05 2014-02-11 Genentech Inc Utilização do anticorpo anti-amilóide beta em doenças oculares
CN107090481A (zh) * 2008-04-17 2017-08-25 惠氏有限责任公司 提高骨形成蛋白产量的方法
KR102018475B1 (ko) 2008-09-15 2019-09-04 제넨테크, 인크. 세포 오스몰농도를 조절하기 위한 조성물 및 방법
EP3431588A1 (en) 2009-08-11 2019-01-23 F. Hoffmann-La Roche AG Production of proteins in glutamine-free cell culture media
PL2475428T3 (pl) 2009-09-11 2015-12-31 Probiodrug Ag Pochodne heterocykliczne jako inhibitory cyklazy glutaminowej
US8470552B2 (en) * 2009-10-12 2013-06-25 Keck Graduate Institute Strategy to reduce lactic acid production and control PH in animal cell culture
US9181233B2 (en) 2010-03-03 2015-11-10 Probiodrug Ag Inhibitors of glutaminyl cyclase
DK2545047T3 (da) 2010-03-10 2014-07-28 Probiodrug Ag Heterocycliske inhibitorer af glutaminylcyclase (QC, EC 2.3.2.5)
ES2684475T3 (es) 2010-04-15 2018-10-03 Abbvie Inc. Proteínas que se unen a beta amiloide
WO2011131748A2 (en) 2010-04-21 2011-10-27 Probiodrug Ag Novel inhibitors
US9428727B2 (en) 2010-04-26 2016-08-30 Novartis Ag Cell culture medium
EP3330370B1 (en) 2010-04-26 2021-02-24 Novartis AG Process for cultivation of cho cells
MX2012012525A (es) * 2010-04-26 2012-11-23 Novartis Ag Medio de cultivo mejorado.
JP6081356B2 (ja) 2010-07-30 2017-02-15 エーシー イミューン エス．エー． 安全で機能的なヒト化抗βアミロイド抗体
MX358739B (es) 2010-08-14 2018-09-03 Abbvie Inc Star Proteinas de union a amiloide beta.
EP2606119A1 (en) 2010-08-20 2013-06-26 Wyeth LLC Cell culture of growth factor-free adapted cells
EP2686313B1 (en) 2011-03-16 2016-02-03 Probiodrug AG Benzimidazole derivatives as inhibitors of glutaminyl cyclase
WO2013006479A2 (en) * 2011-07-01 2013-01-10 Amgen Inc. Mammalian cell culture
FI20115704L (fi) 2011-07-01 2013-01-02 Teknologian Tutkimuskeskus Vtt Oy Vierasproteiinien tuoton parantaminen
US9217168B2 (en) 2013-03-14 2015-12-22 Momenta Pharmaceuticals, Inc. Methods of cell culture
US11390663B2 (en) 2013-10-11 2022-07-19 Regeneron Pharmaceuticals, Inc. Metabolically optimized cell culture
AU2014331776B2 (en) * 2013-10-11 2020-10-22 Regeneron Pharmaceuticals, Inc. Metabolically optimized cell culture
DE102017203908B3 (de) * 2017-03-09 2018-05-30 Evonik Technochemie Gmbh Kulturmedium, umfassend Oligopeptide
US20200199528A1 (en) * 2017-06-16 2020-06-25 Katholieke Universiteit Leuven Cell culture media for differentiation of stem cells into hepatocytes
PL3461819T3 (pl) 2017-09-29 2020-11-30 Probiodrug Ag Inhibitory cyklazy glutaminylowej
US20210253996A1 (en) * 2018-07-03 2021-08-19 Bristol-Myers Squibb Company Methods of producing recombinant proteins
WO2021112925A1 (en) 2019-12-06 2021-06-10 Regeneron Pharmaceuticals, Inc. Anti-vegf protein compositions and methods for producing the same
JP2023513830A (ja) 2020-02-18 2023-04-03 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 哺乳動物細胞培養プロセス
IL300059A (en) 2020-07-23 2023-03-01 Othair Prothena Ltd Anti-Abata antibodies

Family Cites Families (57)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4399216A (en) 1980-02-25 1983-08-16 The Trustees Of Columbia University Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
AU2353384A (en) 1983-01-19 1984-07-26 Genentech Inc. Amplification in eukaryotic host cells
US4713339A (en) 1983-01-19 1987-12-15 Genentech, Inc. Polycistronic expression vector construction
GB8308235D0 (en) 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
JPS6147500A (ja) 1984-08-15 1986-03-07 Res Dev Corp Of Japan キメラモノクロ−ナル抗体及びその製造法
EP0173494A3 (en) 1984-08-27 1987-11-25 The Board Of Trustees Of The Leland Stanford Junior University Chimeric receptors by dna splicing and expression
GB8422238D0 (en) 1984-09-03 1984-10-10 Neuberger M S Chimeric proteins
US5672502A (en) 1985-06-28 1997-09-30 Celltech Therapeutics Limited Animal cell culture
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
DE68925971T2 (de) * 1988-09-23 1996-09-05 Cetus Oncology Corp Zellenzuchtmedium für erhöhtes zellenwachstum, zur erhöhung der langlebigkeit und expression der produkte
US6048728A (en) 1988-09-23 2000-04-11 Chiron Corporation Cell culture medium for enhanced cell growth, culture longevity, and product expression
US6291159B1 (en) 1989-05-16 2001-09-18 Scripps Research Institute Method for producing polymers having a preselected activity
US5395760A (en) 1989-09-05 1995-03-07 Immunex Corporation DNA encoding tumor necrosis factor-α and -β receptors
US5605690A (en) 1989-09-05 1997-02-25 Immunex Corporation Methods of lowering active TNF-α levels in mammals using tumor necrosis factor receptor
NZ235148A (en) 1989-09-05 1991-12-23 Immunex Corp Tumour necrosis factor receptor protein and dna sequences
JPH0396383A (ja) 1989-09-08 1991-04-22 Riso Kagaku Corp 画像形成装置
EP1132471A3 (de) 1989-09-12 2001-11-28 F. Hoffmann-La Roche Ag TNF-bindende Proteine
EP0494955B1 (en) 1989-10-05 1998-07-15 Optein, Inc. Cell-free synthesis and isolation of novel genes and polypeptides
US6657103B1 (en) 1990-01-12 2003-12-02 Abgenix, Inc. Human antibodies derived from immunized xenomice
US5538983A (en) * 1990-05-16 1996-07-23 The Rockefeller University Method of treating amyloidosis by modulation of calcium
US5156964A (en) 1990-08-16 1992-10-20 Cetus Corporation Methods for adapting cells for increased product production through exposure to ammonia
US5122469A (en) 1990-10-03 1992-06-16 Genentech, Inc. Method for culturing Chinese hamster ovary cells to improve production of recombinant proteins
GB9021679D0 (en) 1990-10-05 1990-11-21 Gorman Scott David Antibody preparation
GB9022545D0 (en) 1990-10-17 1990-11-28 Wellcome Found Culture medium
GB2251249B (en) 1990-12-28 1995-06-21 Mogam Biotech Res Inst High-density medium for animal cell culture
JPH059735A (ja) * 1991-07-09 1993-01-19 Kobe Steel Ltd ダイヤモンドの気相合成方法
GB9118664D0 (en) 1991-08-30 1991-10-16 Celltech Ltd Cell culture
US5447851B1 (en) 1992-04-02 1999-07-06 Univ Texas System Board Of Dna encoding a chimeric polypeptide comprising the extracellular domain of tnf receptor fused to igg vectors and host cells
JP3504963B2 (ja) 1993-10-22 2004-03-08 智靖 羅 抗ヒト高親和性ＩｇＥ受容体モノクローナル抗体に係るアミノ酸配列をコードするＤＮＡ断片
US6310185B1 (en) 1994-03-08 2001-10-30 Memorial Sloan Kettering Cancer Center Recombinant human anti-Lewis Y antibodies
US5856179A (en) 1994-03-10 1999-01-05 Genentech, Inc. Polypeptide production in animal cell culture
US5589154A (en) 1994-11-22 1996-12-31 Rutgers, The State University Of New Jersey Methods for the prevention or treatment of vascular hemorrhaging and Alzheimer's disease
US5705364A (en) 1995-06-06 1998-01-06 Genentech, Inc. Mammalian cell culture process
US5721121A (en) 1995-06-06 1998-02-24 Genentech, Inc. Mammalian cell culture process for producing a tumor necrosis factor receptor immunoglobulin chimeric protein
JP4306813B2 (ja) 1995-09-19 2009-08-05 アスビオファーマ株式会社 動物細胞の新規培養方法
CN1233189A (zh) * 1996-05-08 1999-10-27 弗·哈夫曼-拉罗切有限公司 用TNFR-Ig治疗哮喘
US6156570A (en) * 1997-03-20 2000-12-05 Regents Of The University Of Minnesota Process for the continuous culture of cells
US20020012991A1 (en) * 1997-04-07 2002-01-31 Florence Chua Nee Ho Kit Fong Cell culture media for enhanced protein production
US7964192B1 (en) 1997-12-02 2011-06-21 Janssen Alzheimer Immunotherapy Prevention and treatment of amyloidgenic disease
CA2354862A1 (en) 1998-10-19 2000-04-27 Yeda Research And Development Co. Ltd. Treatment of systemic lupus erythematosus by down-regulating the autoimmune response to autoantigens
TWI255272B (en) 2000-12-06 2006-05-21 Guriq Basi Humanized antibodies that recognize beta amyloid peptide
TWI329129B (en) 2001-02-08 2010-08-21 Wyeth Corp Modified and stabilized gdf propeptides and uses thereof
US7318923B2 (en) 2001-04-30 2008-01-15 Eli Lilly And Company Humanized anti-βantibodies
DE60229051D1 (de) 2001-04-30 2008-11-06 Lilly Co Eli Humanisierte antikörper
US20030087372A1 (en) 2001-06-13 2003-05-08 Genentech, Inc. Methods of culturing animal cells and polypeptide production in animal cells
US7320789B2 (en) 2001-09-26 2008-01-22 Wyeth Antibody inhibitors of GDF-8 and uses thereof
BR0307907A2 (pt) 2002-02-21 2011-07-05 Wyeth Corp gasp1: proteìna contendo domìnio de folistatina
US7572763B2 (en) 2002-02-21 2009-08-11 Wyeth Follistatin domain containing proteins
MY139983A (en) 2002-03-12 2009-11-30 Janssen Alzheimer Immunotherap Humanized antibodies that recognize beta amyloid peptide
SG187991A1 (en) 2002-05-02 2013-03-28 Wyeth Corp Calicheamicin derivative-carrier conjugates
AR047392A1 (es) 2002-10-22 2006-01-18 Wyeth Corp Neutralizacion de anticuerpos contra gdf 8 y su uso para tales fines
US20040223966A1 (en) 2002-10-25 2004-11-11 Wolfman Neil M. ActRIIB fusion polypeptides and uses therefor
TWI374935B (en) 2004-08-27 2012-10-21 Pfizer Ireland Pharmaceuticals Production of α-abeta
TWI384069B (zh) 2004-08-27 2013-02-01 Pfizer Ireland Pharmaceuticals 多胜肽之製法
US7300773B2 (en) 2004-08-27 2007-11-27 Wyeth Research Ireland Limited Production of TNFR-Ig

Also Published As

Publication number Publication date
PE20060715A1 (es) 2006-08-15
CA2578137A1 (en) 2006-03-09
JP2012095671A (ja) 2012-05-24
MY146097A (en) 2012-06-29
EP1781803A2 (en) 2007-05-09
RU2418858C2 (ru) 2011-05-20
NO20071571L (no) 2007-05-23
CN101048512B (zh) 2013-04-17
ZA200702487B (en) 2011-10-26
BRPI0514680A (pt) 2008-06-17
ECSP077351A (es) 2008-03-26
SV2006002212A (es) 2006-06-26
ES2599103T3 (es) 2017-01-31
AR050471A1 (es) 2006-10-25
EP2348126A2 (en) 2011-07-27
KR20070073737A (ko) 2007-07-10
NZ591233A (en) 2012-09-28
US7335491B2 (en) 2008-02-26
KR100998857B1 (ko) 2010-12-08
US20060160180A1 (en) 2006-07-20
IL181587A (en) 2011-03-31
WO2006026408A3 (en) 2006-05-04
IL181587A0 (en) 2007-07-04
JP2015133980A (ja) 2015-07-27
TW200615379A (en) 2006-05-16
TWI374935B (en) 2012-10-21
CN101048512A (zh) 2007-10-03
UA89644C2 (ru) 2010-02-25
CR8996A (es) 2007-10-10
RU2007108718A (ru) 2008-10-10
EP2348126A3 (en) 2011-10-12
WO2006026408A2 (en) 2006-03-09
SG155250A1 (en) 2009-09-30
EP1781803B1 (en) 2016-08-24
HN2005000486A (es) 2010-03-29
MX2007002382A (es) 2007-06-15
JP2008511328A (ja) 2008-04-17
CA2578137C (en) 2010-11-09
EG25848A (en) 2012-09-10
AU2005280090A1 (en) 2006-03-09

Similar Documents

Publication Publication Date Title
PE20100147A1 (es) PRODUCCION DE a-BETA
PE20060815A1 (es) PRODUCCION DE TNFR-Ig
ECSP077353A (es) Producción de polipéptidos
RU2014149120A (ru) Способы и композиции для опосредованной нуклеазой направленной интеграции трансгенов
AR069956A1 (es) Procesos para cultivar celulas mamiferas secretoras de proteinas sanguineas heterologas
MX339632B (es) Metodo para producir adamts13 recombinante en cultivo celular.
MX2013014873A (es) Celda de metal-aire con material para intercambio ionico.
PE20150336A1 (es) Metodos y composiciones para la modificacion de adn objetivo dirigida por arn y para la modulacion de la transcripcion dirigida por arn
MX2021005021A (es) Proceso para producir celulas t geneticamente modificadas.
TW200618368A (en) Electrolyte comprising eutectic mixture and electrochromic device using the same
BR112015032267A2 (pt) faixa de células eletroquímicas para realizar um módulo de bateria para veículo elétrico ou híbrido, e método de realização de tal módulo
WO2010087651A3 (ko) 셀 상호간 복합연결망으로 구성된 셀 카트리지
EP2517332A4 (en) ELECTROCHCROMIC WINDOWS WITH WIRELESS POWER SUPPLY
ATE491722T1 (de) Herstellung und reinigung von il-29
EA201890645A1 (ru) Система и способ производства газообразного водорода и газообразного кислорода
AR074955A1 (es) Recepcion discontinua para el agregado de portadores.
MX369544B (es) Metodos y composiciones estabilizadas para reducir los depositos en sistemas de aguas.
NZ592562A (en) An Improved Roof Tile
MX2016012562A (es) Composiciones electroliticas cristalinas solidas y blandas y metodos para su produccion..
AR090255A2 (es) Un montaje de celdas de combustible electroquimicas y un metodo para operar un montaje de celdas de combustible electroquimicas
WO2007030674A3 (en) Use of nucleases to improve viability and enhance transgene expression in transfected cells
BR112012020981A2 (pt) eletrodo para processos eletroquímicos e método para a sua obtenção
BR112015011123A2 (pt) produção eletrolítica de íons manganês (iii) em ácido sulfúrico forte
PE20060711A1 (es) Proceso para la recuperacion electrolitica y electrorrefinacion de cobre
AR071855A1 (es) Sistema y metodo para mejorar las comunicaciones entre vehiculos

Legal Events

Date Code Title Description
FC Refusal